Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ia/Ib Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis

Trial Profile

Phase Ia/Ib Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anselamimab (Primary)
  • Indications Amyloid light-chain amyloidosis
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 06 Jun 2023 Results (n=22) assessing the long term efficacy and safety of CAEL-101 in patients with relapsed/refractory AL amyloidosis, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 14 Sep 2021 Results assessing tolerability and potential amyloidolytic effect of CAEL-101 in patients with light-chain amyloidosis, published in the Blood.
    • 09 Nov 2020 According to a Fortress Biotech media release, positive long-term data from this trial were presented at the International Symposium on Amyloidosis (ISA) 2020.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top